Department of Urology, Second People's Hospital of Banan District, Chongqing, China.
Department of Urology, Traditional Chinese Medicine Hospital, Chongqing, China.
Medicine (Baltimore). 2021 Nov 19;100(46):e27630. doi: 10.1097/MD.0000000000027630.
Recently, some studies have suggested that the association of apurinic/apyrimidinic endonuclease 1 (APE1) gene polymorphism with prostate cancer (PCa) risk, but there are still some controversies. Hence, we elaborated the relationship between APE1 rs1760944 and rs1130409 gene and PCa risk through systematic literature review and meta-analysis.
As of March 2020, EMBASE, PubMed, the Cochrane Library, Science Direct/Elsevier, MEDLINE and CNKI were used for systematic literature retrieval to investigate the correlation between APE1 rs1760944 and rs1130409 gene polymorphism with PCa risk. Meta-analysis was performed using Review Manager and Stata software.
Seven studies were distinguished, consists of 1769 cases of PCa patients and 2237 normal controls. Our results illustrated that there are significant correlation between the APE1 rs1760944 gene polymorphism and PCa in all genetic models (P < .05). The combined odds ratios and 95% confidence intervals were as follows: Additive model (ORs 0.62, 95%, CI [0.39, 0.97]); Codominant model (ORs 0.74, 95% CI [0.58, 0.95]); Dominant model (ORs 0.75, 95%, CI [0.59, 0.95]); Recessive model (ORs 0.63, 95% CI [0.41, 0.96]); Allele model (ORs 0.78, 95% CI [0.65, 0.94]). There also have significant associations between APE1 rs1130409 polymorphisms and PCa in all genetic models (P < .05). The combined odds ratios and 95% confidence intervals were as follows: Additive model (ORs 1.37, 95%, CI [1.01, 1.85]); Codominant model (ORs 1.21, 95% CI [1.01, 1.44]); Dominant model (ORs 1.33, 95%, CI [1.02, 1.73]); Recessive model (ORs 1.74, 95% CI [1.06, 2.85]); Allele model (ORs 1.14, 95% CI [1.00, 1.29]).
This study suggests that APE1 rs1760944 polymorphisms might be a protective factor of PCa, and APE1 rs1130409 is suggested to be a risk factor of PCa. APE1 rs1760944 and rs1130409 polymorphisms may be used in the risk assessment of PCa.
最近，一些研究表明，脱嘌呤/脱嘧啶核酸内切酶 1（APE1）基因多态性与前列腺癌（PCa）风险有关，但仍存在一些争议。因此，我们通过系统文献复习和荟萃分析阐述了 APE1 rs1760944 和 rs1130409 基因与 PCa 风险之间的关系。
截至 2020 年 3 月，我们通过 EMBASE、PubMed、Cochrane 图书馆、Science Direct/Elsevier、MEDLINE 和中国知网（CNKI）进行系统文献检索，以调查 APE1 rs1760944 和 rs1130409 基因多态性与 PCa 风险之间的相关性。使用 Review Manager 和 Stata 软件进行荟萃分析。
我们区分了 7 项研究，包括 1769 例 PCa 患者和 2237 例正常对照。我们的结果表明，在所有遗传模型中，APE1 rs1760944 基因多态性与 PCa 之间存在显著相关性（P<0.05）。合并的优势比和 95%置信区间如下：加性模型（ORs 0.62，95%CI [0.39，0.97]）；共显性模型（ORs 0.74，95%CI [0.58，0.95]）；显性模型（ORs 0.75，95%CI [0.59，0.95]）；隐性模型（ORs 0.63，95%CI [0.41，0.96]）；等位基因模型（ORs 0.78，95%CI [0.65，0.94]）。在所有遗传模型中，APE1 rs1130409 多态性与 PCa 之间也存在显著相关性（P<0.05）。合并的优势比和 95%置信区间如下：加性模型（ORs 1.37，95%CI [1.01，1.85]）；共显性模型（ORs 1.21，95%CI [1.01，1.44]）；显性模型（ORs 1.33，95%CI [1.02，1.73]）；隐性模型（ORs 1.74，95%CI [1.06，2.85]）；等位基因模型（ORs 1.14，95%CI [1.00，1.29]）。
本研究表明，APE1 rs1760944 多态性可能是 PCa 的保护因素，而 APE1 rs1130409 多态性可能是 PCa 的危险因素。APE1 rs1760944 和 rs1130409 多态性可用于 PCa 的风险评估。
